Hiding under the skin: A welcome surprise in psoriasis
暂无分享,去创建一个
[1] Mayte Suárez-Fariñas,et al. Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis , 2012, The Journal of investigative dermatology.
[2] J. Krueger,et al. Putting together the psoriasis puzzle: an update on developing targeted therapies , 2012, Disease Models & Mechanisms.
[3] P. Haslett,et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. , 2012, The Journal of allergy and clinical immunology.
[4] Subhashis Banerjee,et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.
[5] J. Ortonne,et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. , 2012, The New England journal of medicine.
[6] Ping Chen,et al. Interleukin-17 contributes to cardiovascular diseases , 2012, Molecular Biology Reports.
[7] J. Renauld,et al. IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice , 2011, The Journal of Immunology.
[8] A. Menter,et al. Psoriasis: comorbidities and associations. , 2011, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.
[9] Frank O. Nestle,et al. Mechanisms of Disease: Psoriasis. , 2009 .
[10] P. Valdez,et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.
[11] Lawrence Steinman,et al. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage , 2007, Nature Medicine.
[12] R. Kastelein,et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain , 2003, Nature.